Ketamine vs. TMS for Treatment-Resistant Depression: Cost, Effectiveness, Tradeoffs (2026)

For patients with treatment-resistant depression — depression that hasn't responded to two or more antidepressant trials — the two most-asked-about non-pharmaceutical options in 2026 are ketamine therapy and transcranial magnetic stimulation (TMS). Both have FDA-cleared pathways. Both produce clinically meaningful response in 50-75% of TRD patients. They cost dramatically different amounts and require dramatically different time commitments.

I prescribe at-home ketamine in Florida and New Jersey, and I refer patients to TMS clinics when their case fits that pathway better. This is the honest comparison between the two — including which patients I send each direction.

The five-minute summary

How each treatment actually works

Ketamine

Ketamine is a dissociative anesthetic that, at sub-anesthetic doses, produces rapid antidepressant effects through glutamate-mediated neuroplasticity. The drug temporarily blocks NMDA receptors, which triggers a cascade of downstream changes — increased BDNF release, dendritic remodeling, synaptic protein synthesis — that appear to "reset" depressive neural patterns within hours of a single dose.

Treatment formats vary:

• At-home sublingual ($250-$500/month for clinical care + $75-$150/month medication) — physician-prescribed compounded racemic ketamine, taken at home in structured 90-120 minute sessions, with remote physician oversight. The most common 2026 access pathway.
• IV ketamine clinic ($400-$800/session, $2,400-$4,800 induction) — administered by nursing staff, faster onset, higher bioavailability. More expensive and requires clinic time.
• Spravato (intranasal esketamine) ($150-$300 insured copay, $600-$900 cash) — FDA-approved for TRD, REMS-monitored at certified clinics, possibly covered by insurance.

TMS

Transcranial magnetic stimulation uses a focused electromagnetic coil placed against the scalp to deliver pulses that stimulate neurons in the left dorsolateral prefrontal cortex — a region implicated in mood regulation that is hypoactive in depression. Repeated sessions appear to normalize this hypoactivity over weeks, producing antidepressant response.

Treatment is delivered in an outpatient clinic, typically 5 days/week for 6-9 weeks (36 total sessions). Each session is 20-40 minutes, and the patient sits awake in a chair while the device delivers pulses. Insurance coverage for TRD is well-established — most commercial plans, Medicare, and many Medicaid plans cover TMS after documented failure of two antidepressant trials.

A note: these are not identical drugs solving the same problem

It's tempting to frame ketamine and TMS as interchangeable TRD options. They're not. Ketamine works fast (24-72 hours) but the clinical effect cycles between sessions; TMS works slow (2-4 weeks into the course) but the effect tends to be more durable. Patients who respond to one don't necessarily respond to the other. The mechanisms differ enough that "tried ketamine, didn't work" doesn't predict TMS response, and vice versa.

Cost — the variable that often decides

Ketamine cost reality

For most cash-pay patients, at-home compounded sublingual ketamine costs $3,000-$5,000 per year (clinical care + medication). IV clinic ketamine runs $5,000-$15,000 per year. Spravato cash-pay is $14,000-$24,000 per year, but insurance copays bring that to $1,500-$5,000 per year for approved patients.

The cost gap between modalities is the single biggest decision driver for many patients. At-home compounded ketamine is the cheapest path to therapeutic-dose treatment in 2026. See our full ketamine therapy cost breakdown for the per-modality math.

TMS cost reality

TMS is essentially always priced as a per-course package, not per-session. A standard 36-session course runs $10,000-$15,000 at most clinics. Maintenance sessions (typically monthly after the initial course) run $200-$400 each.

Insurance coverage is the meaningful difference. Most commercial insurance covers TMS for TRD after prior authorization with documented failure of 2 antidepressant trials. With insurance, patient out-of-pocket typically lands at $1,000-$3,000 for the full course (deductible + copays). Without insurance, you pay the full $10,000-$15,000.

The cash-pay cost decision

For patients paying out-of-pocket:

• At-home compounded ketamine: $3,000-$5,000/year
• TMS: $10,000-$15,000 for one course

For patients with insurance covering TMS:

• TMS: $1,000-$3,000 for the full course
• At-home compounded ketamine: still $3,000-$5,000/year (insurance won't cover)

This is the crux of the decision: if your insurance covers TMS well, TMS is meaningfully cheaper for the first course. If you're cash-pay or your insurance doesn't cover TMS, ketamine is materially cheaper.

Time commitment — the second-biggest decision driver

Ketamine time

At-home sublingual ketamine sessions take 90-120 minutes plus a 4-hour no-driving window. Most patients schedule sessions on weekends or evenings of off days. Across a 6-12 session induction, total committed time is roughly 12-24 hours over 4-8 weeks. No clinic visits, no commute, no time off work.

IV clinic ketamine adds a 30-60 minute commute each way plus 2-3 hours on-site. A 6-session induction is 18-24 hours of clinic time spread across 2-3 weeks.

TMS time

TMS requires daily clinic visits. The standard protocol is 5 days a week for 6-9 weeks (36 sessions total). Each visit is 30-40 minutes once you account for setup. Across the full course, total clinic time is 18-24 hours, but spread across 36 separate visits with associated commute time.

For patients with full-time jobs, school schedules, or childcare obligations, the daily clinic visit requirement is the most operationally difficult part of TMS. Many patients arrange treatment around lunch hours or take 6-9 weeks of partial leave. At-home ketamine eliminates this friction entirely.

Effectiveness — the data that doesn't decide for you

Real-world response rates for treatment-resistant depression:

• At-home compounded ketamine: 60-75% response rate
• IV ketamine clinic: 65-75% response rate
• Spravato: 60-70% response rate (FDA trial data and real-world)
• TMS: 50-60% response rate (some studies higher, especially with newer protocols like accelerated TMS)

The differences are within population variance — small enough that the modality choice should be driven by access, cost, and clinical fit rather than expected efficacy difference.

What does differ:

• Ketamine produces faster response (24-72 hours after first session vs. 2-4 weeks for TMS)
• TMS response tends to be more durable between courses (one full course often produces 6-12 months of remission; ketamine maintenance is more frequent)
• Ketamine has dissociative effects during sessions; TMS does not
• TMS has no cognitive impairment; ketamine has temporary impairment for 4-5 hours per session

Which patient gets which treatment?

TMS is generally the better fit when:

• Insurance covers TMS well (the cost math favors it)
• The patient can commit to daily clinic visits for 6-9 weeks
• The patient has medical complexity that makes ketamine's transient cardiovascular effects a concern (uncontrolled HTN, recent MI)
• The patient has prior dissociative reactions to anesthetics or psychedelic experiences they want to avoid
• The patient wants the longest possible remission window between courses
• A history of mania or substance use disorder makes ketamine clinically harder

Ketamine is generally the better fit when:

• The patient is cash-pay (the cost difference is decisive)
• Daily clinic visits are operationally impossible (work, geography, caregiving)
• Rapid response is important (24-72 hour onset vs. weeks for TMS)
• The patient also has anxiety, PTSD, or chronic pain that ketamine treats simultaneously (TMS is depression-only)
• The patient can self-administer in a stable home environment

Both can work — many patients try both over time

A common pathway is one course of TMS first (when insurance covers it), then ketamine maintenance for ongoing support if response isn't durable. Or vice versa: ketamine to break out of acute treatment-resistant symptoms, TMS later for longer-term consolidation. The two modalities are not mutually exclusive; they target the same condition through different mechanisms and can be sequenced.

Side effects — what each treatment costs you to receive

Ketamine side effects

During the session: dissociation (the dreamlike state that produces the therapeutic effect — disturbing for some patients, neutral or pleasant for most), transient blood pressure rise (10-25 mmHg systolic), nausea in 15-30% of sessions, heightened sensitivity to environment, time distortion. All resolve within 60-90 minutes of the dose ending.

After: clear-headed by next day. No persistent cognitive impairment, no withdrawal, no daily impairment outside session windows.

Long-term: bladder symptoms (rare at therapeutic intermittent dosing, more common with daily/recreational use), tolerance development (uncommon at session-based intervals).

TMS side effects

During the session: scalp discomfort or tapping sensation under the coil (resolves within sessions as patients acclimate), occasional facial muscle twitching during pulses, mild headache.

After session: transient headache or scalp tenderness for some patients, no cognitive impairment, no impairment of daily activities, can drive immediately after.

Long-term: very low risk of seizure (~0.1% incidence in the 36-session course), no reported tolerance or withdrawal effects. Long-term safety profile is well-characterized after 15+ years of FDA-approved use.

Frequently Asked Questions

Is ketamine or TMS more effective for treatment-resistant depression?

Real-world response rates are similar — roughly 60-70% for ketamine modalities and 50-60% for TMS. The differences are within population variance. Different patients respond to different mechanisms. Failure on one doesn't predict failure on the other. The right choice is driven by access, cost, time commitment, and clinical fit — not by expected efficacy difference.

Why is TMS so much more expensive than at-home ketamine?

TMS requires specialized equipment, FDA-cleared protocols, and a clinic that delivers 36 sessions per patient. The infrastructure overhead is high, and the per-session cost reflects clinic time, equipment depreciation, and physician supervision. At-home ketamine eliminates the clinic infrastructure entirely, which is why per-session cost is roughly 1/10th. Insurance coverage is what brings TMS within range for most patients.

Does insurance cover TMS but not ketamine?

Generally yes for TRD. TMS has been FDA-cleared since 2008 and most commercial insurance plans, Medicare, and many Medicaid plans cover it after prior authorization. Compounded ketamine is rarely covered by insurance because it's an off-label compounded preparation. Spravato (FDA-approved esketamine) is the one ketamine modality with a realistic insurance pathway.

How long does TMS take vs. ketamine?

TMS requires 36 sessions over 6-9 weeks, with daily clinic visits 5 days a week. Each session is 20-40 minutes plus commute. Total clinic time across the course is 18-24 hours. At-home sublingual ketamine requires 6-12 sessions over 4-8 weeks, with no clinic visits — total committed time is 12-24 hours, all at home, on your schedule.

Can you do both ketamine and TMS at the same time?

Generally not simultaneously — most providers want to evaluate response to one before adding the other. But sequencing the two is common. A typical pathway: try TMS first (when insurance covers it) for the cheaper out-of-pocket course; if response is inadequate or doesn't last, add ketamine maintenance. Or start ketamine for rapid acute response, then layer in TMS for longer-term consolidation.

Which has more side effects, ketamine or TMS?

They're different. Ketamine has dissociative effects during the 90-120 minute session window plus 4 hours of impairment afterward, with rare bladder symptoms at very long-term high-dose use. TMS has scalp discomfort during sessions and rare seizure risk (~0.1% incidence). Neither produces persistent cognitive impairment, daily medication burden, or withdrawal between sessions. Ketamine has more "felt" effects during sessions; TMS has fewer perceptible effects.

Is one safer for older adults?

TMS is generally considered slightly safer for older adults — it produces no cardiovascular effects, no cognitive impairment, no fall risk between sessions. Ketamine raises BP and heart rate transiently and produces 4-5 hours of cognitive impairment per session, which carries fall and confusion risk in patients over 75 or with neurodegenerative conditions. For medically complex older adults, TMS is often the first-choice non-pharmaceutical option.

Will trying ketamine make TMS less effective later (or vice versa)?

No — the two work through entirely different mechanisms (glutamate vs. magnetic field neurostimulation), so prior treatment with one doesn't reduce the effect of the other. Many patients have sequenced both successfully.

What about Spravato vs. TMS?

Spravato (FDA-approved esketamine nasal spray) is the most directly comparable to TMS — both are FDA-cleared for TRD, both have insurance pathways. Spravato is faster-onset (hours vs. weeks for TMS) but requires twice-weekly clinic visits during induction. TMS requires daily visits but is shorter per visit. For an FDA-cleared, insurance-covered TRD pathway with the best logistic fit for your life, the choice between Spravato and TMS often comes down to whether daily 30-minute visits or twice-weekly 2-hour visits is more workable for you. See our Spravato vs compounded ketamine guide.

The bottom line

Ketamine and TMS are both legitimate evidence-based options for treatment-resistant depression. Neither is universally better. The decision is driven primarily by:

1. Insurance coverage — if your plan covers TMS well, TMS is meaningfully cheaper
2. Time commitment — daily clinic visits (TMS) vs. at-home sessions (ketamine)
3. Speed of needed response — ketamine in 24-72 hours, TMS in 2-4 weeks
4. Complementary symptoms — ketamine treats anxiety/PTSD/chronic pain simultaneously; TMS is depression-only

If you're in Florida or New Jersey and want to know whether at-home ketamine is appropriate for your specific case (or whether you'd be better served by a TMS referral), the five-minute eligibility check is the start. If TMS is the better fit, I'll say so and refer appropriately.

For more on related topics: Ketamine Therapy Cost covers the per-modality price math. Spravato vs. Compounded Ketamine compares the two ketamine pathways. How to Evaluate an Online Ketamine Clinic covers the framework for vetting any ketamine provider.